IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by Magnetar Financial LLC

Magnetar Financial LLC cut its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 88.9% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 3,000 shares of the medical research company’s stock after selling 23,958 shares during the period. Magnetar Financial LLC’s holdings in IQVIA were worth $590,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of IQV. Synergy Asset Management LLC acquired a new stake in shares of IQVIA during the 4th quarter valued at about $33,000. Avior Wealth Management LLC grew its position in shares of IQVIA by 117.6% during the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock valued at $38,000 after acquiring an additional 87 shares during the period. Versant Capital Management Inc grew its position in shares of IQVIA by 46.0% during the 4th quarter. Versant Capital Management Inc now owns 295 shares of the medical research company’s stock valued at $58,000 after acquiring an additional 93 shares during the period. SBI Securities Co. Ltd. acquired a new stake in IQVIA in the 4th quarter worth about $60,000. Finally, UMB Bank n.a. boosted its holdings in IQVIA by 72.8% in the 4th quarter. UMB Bank n.a. now owns 401 shares of the medical research company’s stock worth $79,000 after buying an additional 169 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Trading Up 0.9 %

IQV opened at $185.85 on Friday. IQVIA Holdings Inc. has a one year low of $179.28 and a one year high of $254.80. The stock has a market capitalization of $32.77 billion, a PE ratio of 24.78, a P/E/G ratio of 1.99 and a beta of 1.50. The business’s 50 day moving average price is $194.94 and its 200 day moving average price is $208.73. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, equities research analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Analysts Set New Price Targets

Several research firms recently issued reports on IQV. Citigroup lowered their price objective on IQVIA from $225.00 to $210.00 and set a “neutral” rating on the stock in a report on Tuesday, March 4th. William Blair reiterated an “outperform” rating on shares of IQVIA in a report on Wednesday, December 11th. Truist Financial reiterated a “buy” rating and issued a $263.00 price objective (up from $261.00) on shares of IQVIA in a report on Monday, February 10th. Bank of America lowered their price objective on IQVIA from $255.00 to $235.00 and set a “buy” rating on the stock in a report on Friday, December 13th. Finally, Morgan Stanley raised their target price on shares of IQVIA from $245.00 to $250.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 11th. Five equities research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $249.05.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.